
Elekta's Nomination Committee's proposal for the Board of Directors prior to the Annual General Meeting 2024

STOCKHOLM – The Nomination Committee of Elekta (EKTA-B.ST) proposes that the Annual General Meeting 2024 reelect Laurent Leksell, who is also proposed to be reelected as Chairman of the Board, Tomas Eliasson, Caroline Leksell Cooke, Wolfgang Reim, Jan Secher, Volker Wetekam and Cecilia Wikström and elect Ann Costello and Jan Kimpen as directors of the Board. Birgitta Stymne Göransson has declined reelection.

Ann Costello is a seasoned executive who brings more than 30 years of experience from the pharmaceutical and diagnostics group Roche, a world leader in diagnostics, oncology and biotechnology. From 2020 to 2023, she led Roche's Diagnostic Solutions, its largest Diagnostics business unit with over 6,000 employees. Prior to this role, she held several executive positions within Roche in both Europe and the United States, including heading up the Pathology business unit and the Centralized Diagnostics & Point of Care Business Area. Ann Costello currently serves on the Board of Directors of Ibx AI and holds a bachelor's degree in biomedical science from the Technological University of Dublin. She is an Irish citizen, resides in Basel, Switzerland, and was born in 1960.

Jan Kimpen is a professor of pediatrics and has extensive experience from both the hospital and academic sectors. Between 2009 and 2015, Jan Kimpen was the CEO of one of the largest hospitals in the Netherlands, University Medical Center Utrecht, with more than 10,000 employees and cancer care as one of the hospital's focus areas. Jan Kimpen was, in 2016, recruited as Philips' first Global Chief Medical Officer, and built a successful department during the time period up until 2023. He currently works as a strategic advisor to various companies and sits on the Board of Directors of Deerns and Twente University of Technology. Jan Kimpen was born in 1958, is a Belgian citizen and resides in Doorn, the Netherlands.

The Nomination Committee's complete proposal will be published in connection with the convening of Elekta's Annual General Meeting 2024, held on September 5, 2024.

Prior to the Annual General Meeting 2024, the Nomination Committee consists of Laurent Leksell, in his capacity as the Chairman of the Board of Elekta and representing his own and related parties' holdings, Jesper Bergström, appointed by Handelsbanken Funds, Katarina Hammar, appointed by Nordea Funds, Patrik Jönsson, appointed by SEB Funds, and Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund. The Chair of the Nomination Committee is Laurent Leksell.

###

For further information, please contact:

Peter Nyquist, Head of Investor Relations

Tel: +46 (70) 5752906, e-mail: Peter.Nyquist@elekta.com

Time zone: CEST: Central European Summer Time



About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](https://www.elekta.com) or follow [@Elekta](https://twitter.com/Elekta) on "X", formerly known as Twitter.